Current Coverage of the mTOR Pathway by Next-Generation Sequencing Oncology Panels

Rita Seeboeck, Victoria Sarne, Johannes Haybaeck

Research output: Journal article (peer-reviewed)Review article

5 Citations (Scopus)


The mTOR pathway is in the process of establishing itself as a key access-point of novel oncological drugs and targeted therapies. This is also reflected by the growing number of mTOR pathway genes included in commercially available next-generation sequencing (NGS) oncology panels. This review summarizes the portfolio of medium sized diagnostic, as well as research destined NGS panels and their coverage of the mTOR pathway, including 16 DNA-based panels and the current gene list of Foundation One as a major reference entity. In addition, we give an overview of interesting, mTOR-associated somatic mutations that are not yet incorporated. Especially eukaryotic translation initiation factors (eIFs), a group of mTOR downstream proteins, are on the rise as far as diagnostics and drug targeting in precision medicine are concerned. This review aims to raise awareness for the true coverage of NGS panels, which should be valuable in selecting the ideal platform for diagnostics and research.

Original languageEnglish
Article number690
JournalInternational Journal of Molecular Sciences
Issue number3
Publication statusPublished - 05 Feb 2019


  • Animals
  • Eukaryotic Initiation Factors/genetics
  • Gene Expression Regulation, Neoplastic
  • High-Throughput Nucleotide Sequencing/methods
  • Humans
  • Mutation
  • Neoplasms/genetics
  • Signal Transduction
  • TOR Serine-Threonine Kinases/genetics


Dive into the research topics of 'Current Coverage of the mTOR Pathway by Next-Generation Sequencing Oncology Panels'. Together they form a unique fingerprint.

Cite this